Biotech 10 February 2026 - 2 June 2026

Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN
····

Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN

Design Therapeutics shares fell 2.3% to $10.20 Tuesday amid a broader biotech selloff. No new trial data has been released since the company’s May 18 update on its Phase 1/2 RESTORE-FA trial for Friedreich ataxia. Design reported 16 patients completed treatment with no serious side effects. The company held $222.8 million in cash at the end of March.
June 2, 2026
Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares rose 1.4% to $233.11 by early afternoon Tuesday, bucking a sharp drop in biotech ETFs. Investors traded on anticipation of management meetings and the pending $739 million XOMA Royalty acquisition. XOMA shares slipped 0.3%. The Ligand-XOMA deal still requires shareholder approval and could face delays.
June 2, 2026
Lakefront Biotherapeutics Shares Drop as LKFT Gets Reevaluated
····

Lakefront Biotherapeutics Shares Drop as LKFT Gets Reevaluated

Lakefront Biotherapeutics shares fell 2.7% in Amsterdam and 1.7% in New York on Monday, extending a 15% decline this year. Bank of America disclosed a 9.3% stake as of May 20, mainly through financial instruments. The company holds €2.98 billion in cash but expects heavy spending in 2026 tied to its Gilead-Ouro partnership and cell therapy exit. Shareholders recently approved the Lakefront rebrand and new ticker LKFT.
June 1, 2026
Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update
····

Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update

Werewolf Therapeutics shares traded near $0.45 Monday, close to a 52-week low, after entities tied to director Luke Evnin sold 141,106 shares under a preset plan, SEC filings show. The company remains under strategic review following a deal with Jazz Pharmaceuticals and repayment of K2 HealthVentures debt. Werewolf reported $46.5 million in cash as of March 31 but warned of “substantial doubt” about its ability to continue as a going concern.
June 1, 2026
Krystal Biotech Near Highs After Insider Filing Ahead of 2026 Data
····

Krystal Biotech Near Highs After Insider Filing Ahead of 2026 Data

Krystal Biotech EVP Thomas John Charles sold 642 shares at $302.03 each on May 26, leaving him with no directly held common stock, according to an SEC filing. KRYS traded at $306.63, near its 52-week high, with the company valued around $9.35 billion. VYJUVEK, Krystal’s gene therapy for DEB, posted Q1 revenue of $116.4 million. Two late-stage readouts are expected this year.
May 28, 2026
Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech
····

Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech

Phio Pharmaceuticals shares rose 1.39% to $1.095 Wednesday as the company prepared to present its PH-762 skin-cancer program at a virtual investor event. CEO Robert Bitterman will discuss the INTASYL platform and Phase 1b results, which showed a 65% response rate among cutaneous squamous cell carcinoma patients. Phio plans to seek FDA feedback on its next trial design in Q2 2026. Market cap stood near $12.55 million.
May 27, 2026
Quince Therapeutics Stock Pauses After Volatile Biotech Moves
····

Quince Therapeutics Stock Pauses After Volatile Biotech Moves

Quince Therapeutics shares closed Friday at $1.10, up 2.8% for the day but down 4.3% for the week. Nasdaq confirmed Quince regained listing compliance after reporting $15.7 million in stockholders’ equity. The company announced the acquisition of Orphai and a planned $187 million private financing. Markets were closed Monday for Memorial Day; trading resumes Tuesday.
May 25, 2026
CSL shares under pressure as traders eye critical week
····

CSL shares under pressure as traders eye critical week

CSL Ltd shares fell 18% last week after a profit warning and a $5 billion non-cash impairment, closing Friday at A$97.96. The company cut its 2026 revenue outlook to $15.2 billion and NPATA to $3.1 billion. Interim CEO Gordon Naylor cited delays in financial benefits from growth initiatives and revenue hits in the U.S., China, and the Middle East. The ASX cash market reopens Monday at 09:59:45 Sydney time.
May 17, 2026
CSL Buyback Near 2017 Lows: Why the ASX Biotech Giant Is Under Pressure
···

CSL Buyback Near 2017 Lows: Why the ASX Biotech Giant Is Under Pressure

CSL Limited bought back 110,004 shares for A$13.69 million on April 30, extending its on-market buyback as shares trade near multi-year lows, according to a May 1 ASX filing. CSL shares closed Friday at A$124.84, barely above a 52-week low and less than half the year’s high. Half-year revenue fell 4% to US$8.3 billion, with net profit after tax down 81% to US$401 million.
May 3, 2026
CSL buyback hits 4 million shares as Australian biotech keeps buying after profit shock
···

CSL buyback hits 4 million shares as Australian biotech keeps buying after profit shock

CSL repurchased 59,751 shares for A$8.57 million on March 4, bringing total buybacks to 4.03 million shares and A$739 million under its ongoing program. The company also issued 39,627 shares after employee performance rights were exercised. The buyback, capped at US$750 million, is scheduled to run through June 30. Shares will trade ex-dividend on March 10.
March 5, 2026
Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns
···

Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns

Amgen shares dropped 2.3% to $377.01 after Kyowa Kirin halted all trials of the experimental drug rocatinlimab due to new safety concerns, including cases of malignancy. Kyowa Kirin had already ended its development partnership with Amgen. The decline outpaced broader healthcare and biotech sector losses. Investors await further safety disclosures and Amgen’s next quarterly results in late April.
March 3, 2026
Pfizer stock jumps as PFE taps a Swiss biotech incubator — here’s what Wall Street is watching next
····

Pfizer stock jumps as PFE taps a Swiss biotech incubator — here’s what Wall Street is watching next

Pfizer shares rose 2.1% to $27.62 Tuesday afternoon after Swiss incubator BaseLaunch announced Pfizer as its newest pharma partner. The move outpaced a flat U.S. healthcare sector. Investors remain focused on Pfizer’s 2026 pipeline and recent obesity-drug data. The FDA granted Priority Review for Pfizer’s hemophilia drug HYMPAVZI, with a decision expected in Q2 2026.
February 10, 2026